HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced seven presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 in Atlanta, Georgia.
Details of Arcus’s Presentations are as follows:
ORAL PRESENTATION:
AB680 (small-molecule CD73 inhibitor)
Title: Development of potent and selective CD73 inhibitors:
Discovery and characterization of AB680
Date and Time: Saturday,
March 30, 2019, 9:30 AM - 9:55 AM
Location: Room A311
POSTER PRESENTATIONS:
AB928 (dual A2aR/A2bR antagonist)
Title: Methods for assessment of the “adenosine fingerprint” in
clinical trials of AB928
Abstract Number: 3168
Date
and Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM
Location: Exhibit
Hall B, Poster Section: 21, Poster Board Number: 21
Title: Altered pan-Ras pathway and activating mutations in EGFR
result in elevated CD73 in multiple cancers
Abstract Number: 4980
Date
and Time: Wednesday, April 3, 2019, 8:00 AM - 12:00 PM
Location: Exhibit
Hall B, Poster Section: 24, Poster Board Number: 3
AB122 (anti-PD-1 antibody)
Title: Longitudinal monitoring of neoepitope-specific T cell
repertoires in patient blood following cancer immunotherapy
Abstract
Number: 4042
Date and Time: Tuesday, April 2, 2019, 1:00
PM - 5:00 PM
Location: Exhibit Hall B, Poster Section: 22,
Poster Board Number: 5
Title: Receptor occupancy and neo-epitope specific T-cell
repertoires in patients with solid tissue tumors following anti-PD-1
therapy
Abstract Number: 4100
Session Date and Time: Tuesday,
April 2, 2019, 1:00 PM - 5:00 PM
Location: Exhibit Hall
B, Poster Section: 24, Poster Board Number: 3
AB154 (anti-TIGIT antibody)
Title: Characterization of AB154, a humanized α-TIGIT antibody,
for use in combination therapies
Abstract Number: 1557
Session
Date and Time: Monday, April 1, 2019, 8:00 AM - 12:00 PM
Location: Exhibit
Hall B, Poster Section: 25, Poster Board Number: 26
AB474 (arginase inhibitor)
Title: AB474, a potent orally bioavailable inhibitor of arginase,
for the treatment of cancer
Abstract Number: 3862
Date
and Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM
Location:
Exhibit Hall B, Poster Section: 12, Poster Board Number: 12
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small-molecule inhibitor of CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.
Source: Arcus Biosciences
